Trial Profile
A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ISTH 0036 (Primary)
- Indications Open-angle glaucoma
- Focus Adverse reactions; First in man
- Sponsors Isarna Therapeutics
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 15 May 2017 Results from this trial published in an Isarna Therapeutics Media Release.
- 15 May 2017 According to an Isarna Therapeutics media release, data from this trial were presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).